Frequency of EBV positivity with different cutoffs in B-cell LPD among different countries
| Country . | EBER+ cases . | Percent . | EBER cutoff 20% . | EBER cutoff 50% . | Diagnosis . | Reference . |
|---|---|---|---|---|---|---|
| Japan | 13/114 | 11.4 | Not specified | Not specified | DLBCL | 11 |
| Japan | 156/1792 | 8.7 | n/a | 156/1,792 (8.7%) | B-LPD* | 12 |
| Japan | 5/460* | 1.1 | 11/460 (2.4%) | 5/460 (1.1%) | DLBCL | 14 |
| Korea | 34/380 | 8.9 | 34/380 (8.9%) | n/a | DLBCL | 13 |
| Korea | 14/468 | 3.0 | n/a | 14/468 (3.0%) | DLBCL | 15 |
| China | 10/212 | 4.7 | n/a | 10/212 (4.7%) | DLBCL | 9 |
| Turkey | 12/178* | 6.7 | Not specified | Not specified | DLBCL | 10 |
| Peru | 28/188* | 14.9 | 28/188 (14.9%) | 17/188 (9.0%) | DLBCL | 4 |
| Mexico | 9/134 | 6.7 | 9/134 (6.7%) | 9/134 (6.7%) | DLBCL | 7 |
| Germany | 4/167 | 2.4 | 4/167 (2.4%) | 4/167 (2.4%) | DLBCL | 7 |
| S/I/A | 8/258 | 3.1 | 7/258 (2.7%) | 5/258 (1.9%) | DLBCL | 6 |
| United States | 5 patients (2002-2007) | n/a | Not specified | Not specified | DLBCL | 5 |
| Saudi Arabia | 16/217 | 7.4 | Not specified | Not specified | DLBCL | 25 |
| Country . | EBER+ cases . | Percent . | EBER cutoff 20% . | EBER cutoff 50% . | Diagnosis . | Reference . |
|---|---|---|---|---|---|---|
| Japan | 13/114 | 11.4 | Not specified | Not specified | DLBCL | 11 |
| Japan | 156/1792 | 8.7 | n/a | 156/1,792 (8.7%) | B-LPD* | 12 |
| Japan | 5/460* | 1.1 | 11/460 (2.4%) | 5/460 (1.1%) | DLBCL | 14 |
| Korea | 34/380 | 8.9 | 34/380 (8.9%) | n/a | DLBCL | 13 |
| Korea | 14/468 | 3.0 | n/a | 14/468 (3.0%) | DLBCL | 15 |
| China | 10/212 | 4.7 | n/a | 10/212 (4.7%) | DLBCL | 9 |
| Turkey | 12/178* | 6.7 | Not specified | Not specified | DLBCL | 10 |
| Peru | 28/188* | 14.9 | 28/188 (14.9%) | 17/188 (9.0%) | DLBCL | 4 |
| Mexico | 9/134 | 6.7 | 9/134 (6.7%) | 9/134 (6.7%) | DLBCL | 7 |
| Germany | 4/167 | 2.4 | 4/167 (2.4%) | 4/167 (2.4%) | DLBCL | 7 |
| S/I/A | 8/258 | 3.1 | 7/258 (2.7%) | 5/258 (1.9%) | DLBCL | 6 |
| United States | 5 patients (2002-2007) | n/a | Not specified | Not specified | DLBCL | 5 |
| Saudi Arabia | 16/217 | 7.4 | Not specified | Not specified | DLBCL | 25 |
n/a, not applicable; S/I/A, Switzerland, Italy, and Austria.
EBER-positive rate was recalculated in these cases after excluding immunodeficiency-associated LPD (including PTLD and HIV-associated lymphoma), autoimmune-associated LPD, and non-DLBCL patients from each study.